

**Supplementary Table S1: Primers used for gene expression analysis, genotyping, and sex determination.**


Gene	NCBI number	Primer sequence (5'→3')	Product length (bp)
<b>Genotyping</b>			
<i>hsFLT1</i>	NM_001159920.2	for: CAAGGACGTAAGTGAAGAGG rev: TTTCTTCCCACAGTCCCAAC	465
<i>Col1a1</i>	/	for: CCATCCCAACAATACATCACA rev: TGGTTTCTTTGGGCTAGAGG	200
tTA	/	for: AAGGGAGCTGCAGTGGAGTA rev-wt: CCGAAAATCTGTGGGAAGTC	297
<b>Sex determination</b>			
<i>IL-3</i>	NM_010556.4	for: GGGACTCCAAGCTTCAATCA rev: TGGAGGAGGAAGAAAAGCAA	544
<i>Sry</i>	NM_011564.1	for: TGGGACTGGTGACAATTGTC rev: GAGTACAGGTGTGCAGCTCT	402
<b>Reference/Housekeeping gene</b>			
<i>Gapdh</i>	XM_011241214.1	for: ACAACTCACTCAAGATTGTCAGCA rev: ATGGCATGGACTGTGGTCAT	121
<b>Glucose and glycogen metabolism</b>			
<i>Glut-1</i>	NM_011400.3	for: GCTGTGCTTATGGGCTTCTC rev: ACACCTGGGCAATAAGGATG	202
<i>Glut-3</i>	NM_011401.4	for: GGAGGAGAACCCTGCATATGATA rev: TGGCTTCATAGTCATCCTTTAGTAAC	96
<i>Gyg</i>	NM_001355261.1	for: TATACTCCTACCTCCCGGCA rev: TTGACAAGGCCATGGTGTTG	223
<i>Gys1</i>	NM_030678.3	for: CTGGCCGCTATGAGTTTTCC rev: TGGGGTGTCCCATAGTTGT	194
<i>Cx26</i>	NM_008125.3	for: ATGCTACGACCACCACTTCC rev: TACGGACCTTCTGGGTTTTG	194
<b>Fatty acid transporters</b>			
<i>Cd36</i>	NM_001159558.1	for: CAGTGCAGAAACAATGGTTGTCT rev: TGACATTTGCAGGTCTATCTACG	137
<i>Fabp</i>	NM_010174.2	for: TTTGTCGGTACCTGGAAGCT rev: CTGTCACCTCGTCGAACTCT	214
<i>Abca1</i>	NM_013454.3	for: CGACCATGAAAGTGACACGC rev: AGCACATAGGTCAGCTCGTG	117
<b>Amino acid transporter</b>			
<i>Snat-1</i>	NM_001166458.1	for: AGCACAGGGCGACATTCTCATC rev: ACAGGTGGAACCTTTGTCTTCTTG	134
<i>Snat-2</i>	NM_175121.4	for: ACAAATGGGTTGTGGTA rev: CCTAGATTTCTCAGCAGTGACAATG	92
<b>Angiogenesis</b>			
<i>Flk-1</i>	NM_001363216.1	for: GGCGGTGGTGACAGTATCTT rev: GTCAGTACAGAGGCGATGA	162

Flt-4	NM_008029.3	for: GTGGCTGTGAAGATGCTGAA rev: TGACACGCAAGAAGTTGGAG	199
Plgf	XM_011244016.1	for: CGTCCTGTGTCCTTCTGAGT rev: CCTCTTCCTCTTCCCCTTGG	200
Vegfa	NM_001025257.3	for: CAGGCTGCTGTAACGATGAA rev: GCATTCACATCTGCTGTGCT	140
Vegfb	NM_011697.3	for: AACACAGCCAATGTGAATGC rev: GGAGTGGGATGGATGATGTC	157
Vegfc	NM_009506.2	for: CAAGGCTTTTGAAGGCAAAG rev: TCCCCTGTCCTGGTATTGAG	159
Cd31	NM_001032378.2	for: ATGACCCAGCAACATTCACA rev: CACAGAGCACCGAAGTACCA	200
hsFLT1	XM_017020485.1	for: AATCATTCCGAAGCAAGGTG rev: TTTCTTCCCACAGTCCCAAC	219
<b>Hypoxia markers</b>			
HO-1	NM_010442.2	for: CACGCATATACCCGCTACCT rev: CCAGAGTGTTTCATTCGAGCA	175
Hif1 $\alpha$	NM_001313920.1	for: TCAAGTCAGCAACGTGGAAG rev: TATCGAGGCTGTGTCGACTG	198
Hif2 $\alpha$	NM_010137.3	for: GCAAGCCTTCCAAGACACAA rev: CCTGAGCTCCTGGTAGATGG	228
Phd1	NM_001357767.1	for: TGCATCAAGTGGAGGAGGAG rev: GATGCTCCTGGACGGTGATA	246
Phd2	NM_001363475.1	for: AGGTGAGAAAGGTGTGAGGC rev: CACAGTACAGTCCAGCAGA	228
<b>Trophoblast and glycogen cell marker</b>			
Plap	NM_007431.3	for: TCAGGGCAATGAGGTCACAT rev: CCTCTGGTGGCATCTCCTTA	161
Igf-2	NM_001315489.1	for: ACCTTCCAGCCTTTTCCTGTC rev: GTAGACACGTCCCTCTCGGA	357
Igf-2R	NM_010515.2	for: TATGTGAACGGCTCTGCTTG rev: GAGCAAGCCTGGTCTGTTTC	200
Pcdh12	NM_017378.2	for: CTTCACTCATCACGCTCAA rev: TGCCCTCTGTCCTCTGCTAT	197
Gcm1	NM_008103.3	for: TGCTCACCTATGGCTCTCCT rev: AAAATTCTGCCAAGCCCTTT	201
<b>Cytokine marker</b>			
Tnfa	NM_001278601.1	for: CGTCAGCCGATTTGCTATCT rev: CGGACTCCGCAAAGTCTAAG	206

**Supplementary Table S2: Antibodies used for Immunoblot and immunohistochemistry.**


Primary antibody	Dilution	Host	Company	Reference number
Anti-CD31 <sup>a</sup>	1:200 in PBS/BSA (0.5 %)	Rat	Dianova (Hamburg, Germany)	DIA-310
Anti-CD31 <sup>b</sup>	1:5000 in 2 % milk powder	Rat	Dianova (Hamburg, Germany)	DIA-310
Anti-CX26 <sup>b</sup>	1:350 in 2 % milk powder	Rabbit	Santa Cruz Biotechnology (Dallas, USA)	#710500
Anti-FLK1 <sup>b</sup>	1:1000 in 5 % milk powder	Rabbit	Cell Signaling Technology (Danvers, USA)	#2479
Anti-FLT4 <sup>b</sup>	1:200 in 0.5 % milk powder	Goat	R&D Systems (Minneapolis, USA)	AF743
Anti-GLUT1 <sup>b</sup>	1:3000 in 2 % milk powder	Rabbit	Novus Biologicals (Centennial, USA)	NB110-39113
Anti-TNF $\alpha$ <sup>b</sup>	1:1000 in 2 % milk powder	Rabbit	Abcam (Cambridge, GB)	ab183218
Peroxidase anti- $\beta$ -actin <sup>b</sup>	1:20000 in TBS-T	Mouse	Sigma-Aldrich (St. Louis, USA)	A3854
Secondary antibody	Dilution	Host	Company	Reference number
Anti-goat IgG-HRP <sup>b</sup>	1:5000 in 0.5 % milk powder	Donkey	Invitrogen (Karlsruhe, Germany)	AB_10990162
Anti-rabbit IgG-HRP <sup>b</sup>	1:5000 in 0.5 % milk powder	Goat	Dako (California, USA)	p0448
Anti-rat IgG-HRP <sup>b</sup>	1:5000 in 0.5 % milk powder	Goat	Invitrogen (Karlsruhe, Germany)	AB_10965062
Anti-rat IgG-Biotin <sup>a</sup>	1:100 in 0.5 % PBS/BSA	Donkey	Invitrogen (Karlsruhe, Germany)	A18743

<sup>a</sup> used for Immunohistochemistry<sup>b</sup> used for Immunoblot analysis.



**Supplementary Figure S1. Impact of placenta-specific hsFLT1 overexpression on phenotype of dams and fetuses at 14.5 and 18.5 dpc.** **A**) Schematic depiction of the interaction between all three transgenes necessary to induce hsFLT1 overexpression in the hsFLT1/tTA/Tpba-Cre mouse model. **B/C**) At 14.5 dpc the litter size was higher in the control group (**B**), and resorptions were only observed in the FGR group (**C**). **D**) More females were born in the control group whereas the sex ratio in the FGR group was equal. **E/F**) At 18.5 dpc the litter size was higher in the FGR group (**E**), and resorptions were only observed in both groups (**F**). **G**) No change in sex ratio was observed at 18.5 dpc. **H-O**) Organ weights and organ/bodyweight ratios at 18.5 dpc: The brain weight (**H**) was significantly reduced in the FGR male group and the kidney weight was significantly increased in the female FGR group (**K**)

whereas the liver and heart weights did not change between the groups (**I, J**). The liver to body weight was significantly increased in males in the FGR group (**M**) and the kidney/body ratio was significantly increased in the females in the FGR group (**O**). The brain/liver weight and the heart/body weight did not change between the groups (**L, N**).  $\mu\text{m}$  **P/Q**) No Correlation of the percentage of fetal vessels (**P**) and maternal sinusoids (**Q**) with the labyrinth area was observed at 14.5 dpc **R**) At 18.5 dpc the percentage of fetal vessels correlated by trend ( $p=0.0876$ ) to the labyrinth area in male FGR placentas but not in females. **S**) Whereas the percentage of maternal sinusoids did not correlate to the labyrinthine area in male and female FGR group at 18.5 dpc. Data is presented in a box plot with median, interquartile range and lower/upper extreme or in a bar graph with standard error. n=number of dams (**B/C, E/F**), fetuses (**D,G**) or fetal organs (**H-O**). \*  $p \leq 0.05$  and \*\*  $\leq 0.01$  as determined by the Mann-Whitney test. Scale bar = 400 .



**Supplementary Figure S2: Impact of placenta-specific hsFLT1 overexpression on the lymphangiogenic marker Flt4 and hypoxia-induced gene expression at 14.5 and 18.5 dpc.** **A)** FLT4 protein level at 14.5 dpc was not changed upon placenta-specific hsFLT1 expression as shown by Western Blot analysis. **B)** The fetal weight significantly correlate to the percentage of PAS-stained area (glycogen containing cells) in the spongiotrophoblast area of male placentas but not in female placentas. **C)** Transcript levels of hypoxia/oxidative stress markers in placentas at 14.5 dpc. Only *Hif2a* was increased by trend in the female FGR groups and *Phd2* was significantly decreased in male FGR and increased in female FGR group compared to controls. **D)** At 18.5 dpc *Hif2a* mRNA was significantly increased in male FGR and *Phd1* mRNA in female FGR group. The mRNA levels were determined by qPCR and normalized to the housekeeping gene *Gapdh*. Data is presented in a box plot with median, interquartile range and lower/upper extreme or in a bar graph with standard error. n=number of placentas. \*  $p \leq 0.05$  as determined by the Mann-Whitney test. Statistical analysis of correlation were calculated by Spearman r test.